Treatment decisions after diagnosis of metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 11, Issue 3, 2012, Pages 155-166

  Cartwright, Thomas H ^a  

^a Ocala Oncology   (United States)

Author keywords

Bevacizumab; Cetuximab; First line treatment; KRAS mutation; Panitumumab

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CEDIRANIB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; COMORBIDITY; DRUG EFFICACY; DRUG TOLERABILITY; FUNCTIONAL STATUS; HUMAN; LIVER METASTASIS; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84865509942     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.11.001     Document Type: Review

References (75)

1. A. Jemal, R. Siegel, J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Colon cancer V 3.2011 http://www.nccn.org Accessed: May 23, 2011
3. Surveillance Epidemiology and End Results Program. SEER stat fact sheets: colon and rectum http://seer.cancer.gov/statfacts/html/colorect.html Accessed: May 23, 2011
4. S. Gill, W. Blackstock, R.M. Goldberg Colorectal cancer Mayo Clin Proc 82 2007 114 129
5. E.K. Abdalla, R. Adam, A.J. Bilchik Improving resectability of hepatic colorectal metastases: expert consensus statement Ann Surg Oncol 13 2006 1271 1280
6. J.N. Primrose Surgery for colorectal liver metastases Br J Cancer 102 2010 1313 1318
7. A. Grothey, D. Sargent, R.M. Goldberg Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment J Clin Oncol 22 2004 1209 1214
8. L.B. Saltz, J.V. Cox, C. Blanke Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer N Engl J Med 343 2000 905 914
9. R.M. Goldberg, D.J. Sargent, R.F. Morton A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 2004 23 30
10. R.M. Goldberg, D.J. Sargent, R.F. Morton Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial J Clin Oncol 24 2006 3347 3353
11. C.S. Fuchs, J. Marshall, E. Mitchell Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study J Clin Oncol 25 2007 4779 4786
12. H. Sørbye, B. Glimelius, A. Berglund Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer J Clin Oncol 22 2004 31 38
13. G. Colucci, V. Gebbia, G. Paoletti Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale J Clin Oncol 23 2005 4866 4875
14. C. Tournigand, T. Andr, E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237
15. P.M. Hoff, A. Hochhaus, B.C. Pestalozzi Cediranib + FOLFOX/XELOX versus placebo + FOLFOX/XELOX in patients (pts) with previously untreated metastatic colorectal cancer (MCRC): a randomized, double-blind, phase III study (HORIZON II) Ann Oncol 21 suppl 8 2010 9 Abstract LBA19 and slides presented at the 35th ESMO Congress; Milan, Italy, October 8-12, 2010
16. E. Van Cutsem, P.M. Hoff, P. Harper Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials Br J Cancer 90 2004 1190 1197
17. J. Cassidy, S. Clarke, E. Diaz-Rubio Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Clin Oncol 26 2008 2006 2012
18. J. Souglakos, N. Androulakis, K. Syrigos FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) Br J Cancer 94 2006 798 805
19. A. Falcone, S. Ricci, I. Brunetti Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment of metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest J Clin Oncol 25 2007 1670 1676
20. H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
21. B.J. Giantonio, P.J. Catalano, N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200 J Clin Oncol 25 2007 1539 1544
22. L.B. Saltz, S. Clarke, E. Diaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
23. A. Gerger, W. Zhang, D. Yang Angiogenesis gene polymorphisms and clinical outcome of metastatic colorectal cancer treated with first-line bevacizumab and oxaliplatin-based chemotherapy J Clin Oncol 29 suppl 2011 abstract 3592 www.asco.org Accessed: November 26, 2011
24. S. Kopetz, P.M. Hoff, J.S. Morris Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance J Clin Oncol 28 2010 453 459
25. A.J. Weickhardt, D. Williams, C. Lee Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): analysis of the phase III MAX study J Clin Oncol 29 suppl 2011 abstract 3531 www.asco.org Accessed: November 26, 2011
26. S.R. Wedge, J. Kendrew, L.F. Hennequin AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer Cancer Res 65 2005 4389 4400
27. P.M. Hoff, R. Ansari, G. Batist Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study J Clin Oncol 19 2001 2282 2292
28. H. Schmoll, D. Cunningham, A. Sobrero mFOLFOX6 + cediranib vs mFOLFOX6 + bevacizumab in previously untreated metastatic colorectal cancer (MCRC): a randomized, double-blind, phase II/III study (HORIZON III) Ann Oncol 21 suppl 8 2010 viii189 Abstract 580O and slides presented at the 35th ESMO Congress, Milan, Italy, October 8-12, 2010
29. E. Van Cutsem, J. Tabernero, L. Rakomy Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC10262-VELOUR) Ann Oncol 22 suppl.5 2011 vi18 [abstract O-0024] and slides presented at the 13th World Conference on Gastrointestinal Cancers; Barcelona, Spain; June 22-25, 2011
30. E. Van Cutsem, C.-H. Khne, E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
31. E. Van Cutsem, C.-H. Khne, I. Lng Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 2011 2011 2019
32. J.-Y. Douillard, S. Siena, J. Cassidy Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 2010 4697 4705
33. J.Y. Douillard, S. Siena, J. Cassidy Final results from PRIME: randomized phase III study of panitumumab (pmab) with FOLFOX4 for firstline metastatic colorectal cancer (mCRC) J Clin Oncol 29 suppl 2011 abstract 3510 www.asco.org Accessed: November 26, 2011
34. C. Bokemeyer, I. Bondarenko, J.T. Hartmann Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol 22 2011 1535 1546
35. T.S. Maughan, R.A. Adams, C.G. Smith Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 377 2011 2103 2114
36. K. Tveit, T. Guren, B. Glimelius Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the NORDIC VII study (NCT00145314 ) Ann Oncol 21 suppl 8 2010 9 Abstract LBA20 and slides presented at the 35th ESMO Congress; October 8-12, 2010, Milan, Italy
37. J.R. Hecht, E. Mitchell, T. Chidiac A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 2009 672 680
38. J. Tol, M. Koopman, A. Cats Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 2009 563 572
39. W. De Roock, D.J. Jonker, F. Di Nicolantonio Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 2010 1812 1820
40. S. Tejpar, C. Bokemeyer, I. Celik Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab J Clin Oncol 29 suppl 2011 abstract 3511 www.asco.org Accessed: November 26, 2011
41. C. Kohne, P. Rougier, C. Stroh Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): a meta-analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status Paper presented at: Gastrointestinal Cancers Symposium: Science and Multidisciplinary Management of GI Malignancies; January 22-24, 2010. Orlando, FL; Abstract 406 www.asco.org Accessed: November 26,2011
42. D. Jonker, C. Karapetis, C. Harbison High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): results from NCIC CTG CO.17A phase III trial of cetuximab versus best supportive care (BSC) J Clin Oncol 27 suppl 2009 abstract 4016 www.asco.org Accessed: November 26, 2011
43. M. Ychou, F. Viret, A. Kramar Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases Cancer Chemother Pharmacol 62 2008 195 201
44. G. Ramadori, S. Cameron Effects of systemic chemotherapy on the liver Ann Hepatol 9 2010 133 143
45. P. Pessaux, M.-P. Chenard, P. Bachellier, D. Jaeck Consequences of chemotherapy on resection of colorectal liver metastases J Visceral Surg 147 2010 e193 e201
46. H.A. Marsman, A.E. Van Der Pool, J. Verheij Hepatic steatosis assessment with CT or MRI in patients with colorectal liver metastases after neoadjuvant chemotherapy J Surg Oncol 104 2011 10 16
47. H. Nakano, E. Oussoultzoglou, E. Rosso Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy Ann Surg 247 2008 118 124
48. Y. Kishi, D. Zorzi, C.M. Contreras Extended postoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases Ann Surg Oncol 17 2010 2870 2876
49. J.N. Vauthey, T.M. Pawlik, D. Ribero Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases J Clin Oncol 24 2006 2065 2072
50. G. Folprecht, T. Gruenberger, W.O. Bechstein Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial Lancet Oncol 11 2010 38 47
51. C. Garufi, A. Torsello, S. Tumolo Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial Br J Cancer 103 2010 1542 1547
52. C. Kohne, C. Bokemeyer, S. Heeger Efficacy of chemotherapy 1 cetuximab according to metastatic site in KRAS wild-type metastatic colorectal cancer: analysis of CRYSTAL and OPUS studies Ann Oncol 22 suppl 5 2011 v10 Abstract O-0002 and slides presented at: the 13th World Conference on Gastrointestinal Cancers; June 22-25, 2011, Barcelona, Spain
53. F. Bertolini, N. Malavasi, L. Scarabelli FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer Br J Cancer 104 2011 1079 1084
54. J. Tabernero, F. Ciardiello, F. Rivera Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study Ann Oncol 21 2010 1537 1545
55. T.J. Ciuleanu, V. Nikolic, E. Shmueli Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) J Clin Oncol 29 suppl 2011 abstract 3580 www.asco.org Accessed November 27, 2011
56. M.W. Saif, J. Reardon Management of oxaliplatin-induced peripheral neuropathy Ther Clin Risk Manag 1 2005 249 258
57. M. Koopman, N.F. Antonini, J. Douma Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial Lancet 370 2007 135 142
58. M.T. Seymour, T.S. Maughan, J.A. Ledermann Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial Lancet 370 2007 143 152
59. S.P. Ackland, M. Jones, D. Tu A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer Br J Cancer 93 2005 1236 1243
60. H.X. Chen, M. Mooney, M. Boron Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301 J Clin Oncol 24 2006 3354 3360
61. F.F. Kabbinavar, J. Hambleton, R.D. Mass Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J Clin Oncol 23 2005 3706 3712
62. S. Siena, J. Cassidy, J. Tabernero Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared with FOLFOX4 alone as firstline treatment (tx) for metastatic colorectal cancer (mCRC): Results by Eastern Cooperative Oncology Group (ECOG) performance status (PS) J Clin Oncol 29 suppl 2011 abstract 3567 www.asco.org Accessed: November 27, 2011
63. C. Tournigand, A. Cervantes, A. Figer OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancera GERCOR study J Clin Oncol 24 2006 394 400
64. B. Chibaudel, F. Maindrault-Goebel, G. Lledo Can chemotherapy be discontinued in unresectable metastatic colorectal cancer: The GERCOR OPTIMOX2 study J Clin Oncol 27 2009 5727 5733
65. T.S. Maughan, R.D. James, D.J. Kerr Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial Lancet 361 2003 457 464
66. R.A. Adams, A.M. Meade, M.T. Seymour Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet Oncol 12 2011 642 653
67. J. Tabernero, E. Aranda, A. Gomez Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): the MACRO trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]) J Clin Oncol 28 suppl 2010 abstract 3501 www.asco.org Accessed: November 27, 2011
68. M.E. Lacouture, E.P. Mitchell, B. Piperdi Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer J Clin Oncol 28 2010 1351 1357
69. M.E. Lacouture, M.J. Anadkat, R.J. Bensadoun Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities Support Care Cancer 19 2011 1079 1095
70. J. Cassidy, L.B. Saltz, E. Van Cutsem Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of over 6,000 patients in randomized phase II and III studies Ann Oncol 21 suppl 6 2010 vi11 abstract O-0003
71. E. Van Cutsem, F. Rivera, S. Berry Anticoagulant medication exposure in bevacizumab-treated patients: subgroup analysis from the bevacizumab-expanded access trial (BEAT) Ann Oncol 21 suppl.6 2010 vi73 abstract P-0157
72. H.L. Nguyen, J. Hwang Treatment of metastatic colorectal cancer in the elderly Curr Treat Options Oncol 10 2009 287 295
73. M.F. Kozloff, M.M. Sugrue, D.M. Purdie Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): results from the BRiTE observational cohort study J Clin Oncol 26 suppl 2008 abstract 4026 www.asco.org Accessed: November 27, 2011
74. T.J. Price, D. Zannino, K. Wilson Geriatric subgroup of AGITG MAX trial: International randomized phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC) J Clin Oncol 29 suppl 4 2011 abstract 510 www.asco.org Accessed: November 27, 2011
75. D. Smith, M. Rouyer, P. Noize Effectiveness and safety in very elderly patients treated by bevacizumab (BV) plus chemotherapy in first-line therapy of metastatic colorectal cancer: Results of ETNA, a French cohort study J Clin Oncol 29 suppl 4 2011 abstract 555 www.asco.org Accessed: November 27, 2011